{"name":"101 Therapeutics","slug":"101-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"101-PGC-005","genericName":"101-PGC-005","slug":"101-pgc-005","indication":"Other","status":"phase_2"},{"name":"Placebo + SOC","genericName":"Placebo + SOC","slug":"placebo-soc","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"101-PGC-005","genericName":"101-PGC-005","slug":"101-pgc-005","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo + SOC","genericName":"Placebo + SOC","slug":"placebo-soc","phase":"phase_3","mechanism":"Placebo combined with standard of care provides a control comparator in clinical trials to assess the incremental benefit of an investigational therapy.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPQ3dBSk14YURvcWRnaUNtWmREN2s2MFhjNHJKRmtkcDZLTjA5QW0zTU92WWJaS3h4X1NyMlA1R1VmMjNzM2FIMUFFYjdjNlBncmpjYlYtalQwNFdXX0FtU080MzdpRV9FMDNtOTZGLXNXbW5HZVlOVXRvVFBHUWk3ZW9MSllNOUE5VG5uSTQ2Y0l2YUhESS1yRFJqWG9kelUxN2lHYk13aXk?oc=5","date":"2026-03-25","type":"pipeline","source":"Yahoo Finance","summary":"NRx Pharmaceuticals (NRXP) Looks to Score Double With ANDA and NDA Filings For NRX-101 - Yahoo Finance","headline":"NRx Pharmaceuticals (NRXP) Looks to Score Double With ANDA and NDA Filings For NRX-101","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNYzY2cThpajhSZzl0R2RSa1VZcGx2OEdMT2g2bEloRlV5WkgtQ0hUSXVzR24wWHYwdVZGTUJXLXlYQWJFejl5Rm5LZ0VCREJwTHVGbDFFcDBTRExpRDZ4dmZ5WmZIQlJxVjJudUItQmotMWl1bFpSN3VLZG9yNGw1aDdFdFZuTldiUnprZnZBTElNUzNKSHhibHNGVnlGNTg1WGFRT3puQ0toMkNzWjVlMjNOd2theFFoMW5ieE9saS1IY3l3LTZwT3M4U2tpMzNzaHp6STJFWmRSVG9nSHE4MFlTSUNwWDVIcjlnTGJMUWFVM05iZDdST01XUmVSeGQwMUhR?oc=5","date":"2026-03-09","type":"deal","source":"prnewswire.com","summary":"NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - prnewswire.com","headline":"NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQSXhZVnJGQ2tSd0VLRUh5bTJfV25LMjJYSGtnNHZnOFA3bUNHQ0VWcE9oRzJfdnFWV2RkOTVoRFgwMC0weEdXcTFGeDZTcDFWclQxRWFpdGJraTAzbkg1RzMtZVdvZmh5MEwtcEVJLXY5LTZOWkhZazIyT3RqNW1YLURsSGdzVHh6dDgxZDFKbi1TdHZFZEtZSnNvXzhyWmxmeERSTmxVRVZmR3lDLTVKMUd6YjZ1dlBJOHdUckdJbnBUMDFwTGs5bGVLQ2NiYjQwbThQbHRXTlk3SG1kbC1pQXVoMDdUdWd3aHJj0gHwAUFVX3lxTFBYR2FncXlCNXkwWTItWHZudTAyZ0tBX1UyRkpEMG56WWJaT1ZObE5XajFPVkNjVXJkSmRzZDFDTnJOWF8wTWUtY3FYc2YtRHFpX09kMWh2SV9oVU5rbUdnZGNSMUlOUkt3ZkRYeVd5UmFYamlrUGNSRnhKSjFKRnJQenJMRTJXYUo5cWNSSFdUZzJqTkxGekZ4Z3oyMXNXQnZqWW5jQmRCcGJvdEh4NkdONGFjRUVZRkxWN0N1WGxSbERaQXc0RGZHa0pVcnFzUUhXUFlHb1NPRUMzXy1nUDZFcmJHcXZGT25kT0lNVlVncA?oc=5","date":"2026-03-03","type":"trial","source":"simplywall.st","summary":"Aardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101 - simplywall.st","headline":"Aardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxQUDRBdG5ROWF3V01scDByZ3lkZzYyNUlKX3o4R2tveUNRTVhLbEhLVU10U05la0lnZWFnazdKRUJZa1RzMjlsYzI4STdqbTAzRF9tZndJUXh4U0FCRjZrdHhlTFQxZ2k3bEU2dTZad3FYYzczNDM2Z19XMi0xRTdzMW5zN1RDdG9YSVBPaWIyTzRVZmJGR3Y5V3VlTl9lV2lSOF9SOUhHeHlyT0t1ZGttUENmeUdyUl83cklJeThlM284dUhTMloxaU9td1FrYjNfVkVWeEVvMkdwSjJBcFFoWV9fU05tMjBXcGwyS3BjTnhIWVhCNFBfckxKNjlKQXRLVUxlWWpRdmFEUHFFb05IWTVwSnBvV1JZelE?oc=5","date":"2026-01-07","type":"pipeline","source":"businesswire.com","summary":"RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta - businesswire.com","headline":"RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNOURsNWtid3dYRXlWNGhabUxVdFgxQk5fZ0dhcFVrMmdWYWZhRnRkaTliT1I2TE5IQnhVRHY5cGI1VjlqM01YU3JzQjBhVEl6eW4wOWxUUnE0UXlVQWs2eGtVTnJWdmE5X3RkNW5iaVR0b3BxLVI5TDdTOGlFeUp0czdhNUtrLUVMdXUzaEExWU5MaHVLQmZQeTBGUThScXZ5Ull5Wm1oZUlYVDVSN3REQ3B6WUpNeHd5VUo2N2NhNWl6STVQSG9HOVdzYTVQRV9xa3hEWXNEWE1TWXc?oc=5","date":"2025-12-03","type":"pipeline","source":"Investing News Network","summary":"NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation - Investing News Network","headline":"NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQYkRWSk5Nd01WczAycDFNM0tmcU1YWnN5bUxJbFpnT2dwZUFQVmEzbHFVZlBhcEVxTElKR1kySGxycndOMnJnZG40MkxKWmZaYXBjWEhKR0puSVhfSTZWZ0pEMFlrMEhyNzVhNUVINEVBSWc3eTczQVJLMklUcHk5ZlpweXlNc1czcWc5Q0lmTklKRkxQeVhWaDV6SE1yMzBFRTViUXA2LWx3Tk5pUTBPdEh5N1RBVHRlXzIxWTd5Nktubi1oc19HN29B?oc=5","date":"2025-12-03","type":"pipeline","source":"NewMediaWire","summary":"NRx Pharmaceuticals (NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment - NewMediaWire","headline":"NRx Pharmaceuticals (NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPT2Rpa2FxOVdJY3p5VVRBR1dleXZfVktET0tEWVltcjJJZmxQQkJSTnlwcy1Ea0dkcFVveUxVcFJ2NmNwQlZTbFhxOUE3RTY1ZUZBRGRnaWt0ZHdSODdVdWZWZ0NoamdkX2g2WU9UbUJQOE12SnhXbEVVRlRRVlZ5T1VlWFB0VDVmMjU2b2ZtVTZQMnNfOS04S0daOXBIalNRSEtMS0tJNnVsdk0?oc=5","date":"2025-10-09","type":"pipeline","source":"The Pharma Letter","summary":"Nilo Therapeutics launches with $101 million Series A financing - The Pharma Letter","headline":"Nilo Therapeutics launches with $101 million Series A financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9wNWdYSThzZGg2elJxOEtaaC1yNi1kUm9rakFqc0lGZFNSWFM3d0c1bnVFZFJEWDZxamdtX3NXT0x4Rl85SE9rQUJZbWFCWUJIVmhsaHlUbXlYMzkyOXZYQUlJOHlYTmVMX3hIM0dFWVFIbk9qX2RVbmVkQUlMdw?oc=5","date":"2025-09-11","type":"trial","source":"ALS News Today","summary":"AP-101 holds promise for some with ALS, topline data show - ALS News Today","headline":"AP-101 holds promise for some with ALS, topline data show","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5LTEtPSk5IQ1BDQ0Zndi1JVGp4TWcyN24xWUl6TGliRVgwNWRCMTRRdGZiSXJlN0RMVkl3UVFzblZMOWoyTVd2TnhvMTRpSXR3SW9Qc1UtSTFlNEszeUhR?oc=5","date":"2025-06-11","type":"trial","source":"Nature","summary":"TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial - Nature","headline":"TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the rand","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQMG9nTndYUDg4UWNMWnVqQXNLWG0zU3lPZmN0YnpXZUt6QUU3RHdBX1AwNUJhLTd6b0t3S3NnVmpNS0M2MzRQODBLcEVfSjY2ZFl1QmtPTzFzTHQ3bUNNckVFUEFhNU9iQkZUMWxFZ0tNTFdtMDBZQXA3Vm0yZVNMaXFaSmxlTXZvNG1lVjVwYmxHOWpxTGNzNk5IcGFfX2hwdzJ0cHp4N2FWSjMyeTcwLU8wWE5LOXpENmFSQ2ZybWUycExxVlhYTVZTUng0MVBROUNkNXc2TVN4b2VjLVl3eDFUT2ZrNDZtdlpKV0tkWWlPems?oc=5","date":"2025-02-25","type":"regulatory","source":"prnewswire.com","summary":"Veloxis Pharmaceuticals Receives Approval from USAN for \"Pegrizeprument\" as Nonproprietary Name for VEL-101 - prnewswire.com","headline":"Veloxis Pharmaceuticals Receives Approval from USAN for \"Pegrizeprument\" as Nonproprietary Name for VEL-101","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxORWZnd0pXV0JRNllKQy1CUkpnWUpCY2hlZ28zcUxKODJ3X2hzMzBJNVFRYm5QRUIzTDB1VzFrZ0gtTFNBWS04emN5YUtmRFN5aDJuSVNsYnRNdVRmVVd2cDMtYTNMc0tNTHk0aTZpVWxvNjFnWXpNWUJFb1YwNG5KVU15c3JGSE9wWGt0Yks2Vk1Jc0F2UXlhZEk2Mks1MEhWZDhYSzJ5OG5NWElpRldpT1VnQ2NOeTl2?oc=5","date":"2024-10-04","type":"trial","source":"Clinical Trials Arena","summary":"Island Pharmaceuticals trials prevention and therapy benefit of dengue drug - Clinical Trials Arena","headline":"Island Pharmaceuticals trials prevention and therapy benefit of dengue drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNUmFZTHFZT2RWUlBZSFd3aDlSbXFrZURCSFZhSk4wZFN3c05zemJaQzRiYWpxendDd3A0R0JzbWZGOW5HTGMwNDM3MDM1a0x4X0tBdmVhR2Z1a0NKYjc0WmhzSFVCSDdXVy13SE5HY0xaZnVyalA3NjRrZFBuSGdSYlp1U08xT0FjVnlTOVpfWkNabXlhdGRBNkdOQQ?oc=5","date":"2023-10-30","type":"pipeline","source":"C&EN","summary":"Why small-molecule drug discovery is having a moment - C&EN","headline":"Why small-molecule drug discovery is having a moment - C&EN","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}